Covered recipient · General Payments record
DOUGLAS EDWARD RIMMER
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$1,768.19
- Reported across 69 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $816.99 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABIOMED | $272.15 | 2 |
| ABBVIE INC. | $153.42 | 6 |
| Lilly USA, LLC | $125.00 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $125.00 | 1 |
| GENZYME CORPORATION | $118.55 | 5 |
| AIMMUNE THERAPEUTICS, INC. | $22.87 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.40 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950539 | CMS |
| ABBVIE INC. | $16.16 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950541 | CMS |
| ABBVIE INC. | $16.40 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950543 | CMS |
| ABBVIE INC. | $75.00 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950545 | CMS |
| ABBVIE INC. | $14.54 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950547 | CMS |
| ABBVIE INC. | $14.92 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105950549 | CMS |
| ABIOMED | $134.90 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142271325 | CMS |
| ABIOMED | $137.25 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142271277 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $22.87 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146984155 | CMS |
| GENZYME CORPORATION | $31.12 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139714444 | CMS |
| GENZYME CORPORATION | $22.88 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139714452 | CMS |
| GENZYME CORPORATION | $26.00 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139714474 | CMS |
| GENZYME CORPORATION | $23.62 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139714492 | CMS |
| GENZYME CORPORATION | $14.93 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139714500 | CMS |
| Lilly USA, LLC | $125.00 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136143713 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $125.00 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137662566 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.